EP0961619A1 - Promedicaments hydrolysables pour la liberation de medicaments anticancereux dans des cellules metastatiques - Google Patents

Promedicaments hydrolysables pour la liberation de medicaments anticancereux dans des cellules metastatiques

Info

Publication number
EP0961619A1
EP0961619A1 EP97944519A EP97944519A EP0961619A1 EP 0961619 A1 EP0961619 A1 EP 0961619A1 EP 97944519 A EP97944519 A EP 97944519A EP 97944519 A EP97944519 A EP 97944519A EP 0961619 A1 EP0961619 A1 EP 0961619A1
Authority
EP
European Patent Office
Prior art keywords
peptide
aminobenzyl
amino
hydrolyzable
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97944519A
Other languages
German (de)
English (en)
Other versions
EP0961619A4 (fr
Inventor
Raymond Firestone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP0961619A1 publication Critical patent/EP0961619A1/fr
Publication of EP0961619A4 publication Critical patent/EP0961619A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention is directed to hydrolyzable prodrugs for delivery of therapeutic drugs to metastatic cells, particularly anticancer drugs.
  • Metastasis is the hallmark of cancer.
  • a tumor that does not metastasize is termed "benign” because it poses a threat of survival that is small compared to a "malignant" tumor that does metastasize (McGuire, New En ⁇ . J. Med.. 320:525 (1989)).
  • Metastasis involves a sequence of events that few cells can successfully complete (Sanchez, Am. J. Med. ScL 292:376 (1986); Poste, Nature. 283:139 (1980)). Metastatic cells must break away from the primary tumor, survive attack by the immune system during transit in the blood, lodge somewhere while resisting the shear force of the moving blood stream, penetrate basement membrane to reach a safe haven where they can multiply, and finally create a blood supply of their own when the demand for nourishment of the growing metastatic tumor exceeds what is available locally by diffusion. Metastatic cells are not a representative sample of the tumor (itself highly heterogeneous) (Poste, Ann. New York Acad. Sci., 397:34 (1982); Heppner, Cancer Res..
  • metastases are very small and therefore comparatively accessible to chemotherapy, they are highly resistant to present day drugs, for in spite of heavy medication, survival rates for e.g., phases 2 and 3 breast carcinoma (lymph node involvement signaling spread) are very low compared to phase 1 (no spread). In the absence of spread, the survival rate is 70% or greater; in the presence of spread, it is less than 10% (McGuire, New En ⁇ . J. Med.. 320:525 (1989)). Inhibiting as contrasted with killing metastases can only prolong life a short while because by the time cancer is typically diagnosed, metastasis has already taken place.
  • such anti -metastatic reagents should be usable against many types of metastases and not depend for their activity on characteristics of the primary tumor cells that might not be shared by the metastases.
  • such anti-metastatic reagents should be readily absorbed and lack toxicity, particularly in patients who are already subject to regimens consisting of multiple drug treatment.
  • a hydrolyzable prodrug according to the present invention comprises an amino-terminal capped peptide covalently linked to a therapeutic drug through a self- immolating spacer of sufficient length to prevent the occurrence of steric hindrance.
  • the amino-terminal capped peptide is a substrate for a peptidohydrolase located on the surface of a metastatic cell
  • the peptidohydrolase is cathepsin B or collagenase IV.
  • the peptidohydrolase is cathepsin B.
  • the amino-terminal capped peptide is benzyloxycarbonylphenylalanyllysine, benzyloxycarbonylvalinyllysine, D- phenylalanylphenylalanyllysine, benzyloxycarbonylvalinylcitrulline, t-butyloxyca ⁇ >onylphenylalanylysine, benzyloxycarbonyl- alanyllarginylarginine, benzyloxycarbonylphenylalanyl-N-tosylarginine,2- aminoethylthio-succinimidopropionylvalinylcitrulline, 2-aminoethylthio- succinimidopropionyllysylphenylalanyllysine, acetylphenyialanyllysine, or benzyloxycarbonylphenylalanyl-O-benzoylthreonine.
  • the therapeutic drug is an anticancer drug.
  • the anticancer drug is doxorubicin, mitomycin C, taxol, esperamycin, or camptothecin.
  • a particularly preferred anticancer drug is doxorubicin.
  • PABC p_-aminobenzyl carbonyl
  • the hydrolyzable prodrug can further comprise a peptide derived from a protein to which metastatic cells adhere in establishing colonies covalently linked to the therapeutic drug.
  • the peptide is a RGD-derived active peptide or a YIGSR-derived active peptide.
  • the peptide is YIGSR (SEQ ID NO:1) or GRGDS (SEQ ID NO:2).
  • Preferred hydrolyzable prodrugs according to the present invention include benzyloxycarbonylphenylalanyllysyl-rj-aminobenzyl carbamoyldoxorubicin, acetylphenylalanyllysyl- ⁇ -aminobenzyl carbamoyldoxorubicin, acetylphenylalanyliysyl-g-aminobenzyl carbamoylmitomycin C, benzyloxycarbonylphenylalanyllysyl-p_-aminobenzyl carbonyl-7-paclitaxel, acetylphenylalanyllysyl-p-aminobenzyl carbonylcamptothecin, 2-aminoethylthio-succinimidopropionyl- valinyicitrullinyl-BHMS-didoxorubicin, 2-aminoethylthio- succinimidopropionyl
  • Another aspect of the present invention is a method for delivering a therapeutic drug to a metastatic cell comprising the steps of: (1) contacting a hydrolyzable prodrug according to the present invention with a metastatic cell;
  • composition comprising:
  • Figure 1 is a depiction, showing structural formulas and reaction conditions, of the initial stages in the synthesis of the hydrolyzable prodrug Ac-Phe-Lys-PABC-Dox;
  • Figure 2 is a similar depiction of the final stages in the synthesis of Ac-Phe-Lys-PABC-Dox;
  • Figure 3 is a similar depiction of the synthesis of the hydrolyzable prodrug Ac-Phe-PABC-MMC, beginning with an intermediate in the synthesis of Ac-Phe-Lys-PABC-Dox prior to the coupling of the doxorubicin residue;
  • Figure 4 is a similar depiction of the initial stages of the synthesis of the hydrolyzable prodrug Z-Phe-Lys-PABC-Paclitaxel
  • Figure 5 is a similar depiction of the final stages of the synthesis of the hydrolyzable prodrug Z-Phe-Lys-PABC-Paclitaxel
  • Figure 6 is a similar depiction of the early stages of the synthesis of the hydrolyzable prodrug CA-SP-Lys-Phe-Lys-BHMS-Dox 2 ;
  • Figure 7 is a similar depiction of the intermediate stages of the synthesis of CA-SP-Lys-Phe-Lys-BHMS-Dox 2 ;
  • Figure 8 is a similar depiction of the final stages of the synthesis of CA-SP-Lys-Phe-Lys-BHMS-Dox 2 ;
  • Figure 9 is a table showing the killing of BT-20 tumor cells, which are high-cathepsin B-secreting cells, and MCF-10A tumor cells, which are low-cathepsin B-secreting cells, by several hydrolyzable prodrugs and control compounds in the presence or absence of the cathepsin inhibitor CA- 074;
  • Figure 10 is a table showing the killing of BT-20 tumor cells at various times and prodrug concentrations with several hydrolyzable prodrugs and a control compound;
  • Figure 1 1 is a table showing the killing of BT-20 and MCF-10A tumor cells at various times and prodrug concentrations with the hydrolyzable prodrug CA-SP-Lys-Phe-Lys-BHMS-Dox 2 ;
  • Figure 12 is a table showing the stability of hydrolyzable prodrugs according to the present invention under physiological conditions in the presence or absence of cathepsin B.
  • One new approach to developing reagents specific for metastatic cells takes advantage of the properties of the metastatic cells themselves, particularly those properties possessed by the metastatic cells that allow them to spread through the body and adhere to specific tissues.
  • One such property is the ability of metastatic cells to penetrate basement membrane (Sanchez, Am. J. Med. Sci. 292:376 (1986); Poste, Nature. 283:139 (1980)), shared only by the peripheral cells of the primary tumor (Poole, Nature. 273:545 (1978); Shamberger, Nature. 213:617 (1967); Graf, Lab. Invest.. 45:587 (1981 ); Baici, Inv. Metas.. 4:13 (1984); Duffy, Eur. J. Cancer Clin. Oncol.. 23:583 (1987)) and by virtually no normal body cells.
  • Metastatic cells do this by means of hydrolytic enzymes which they secrete into the medium (Duffy, Eur. J. Can. Clin. Oncol.. 23:583 (1987); MacKay, Cancer Res.. 50:5997 (1990); Goldfarb, Sem. Thromb. Hemostas.. 12:294 (1986); Pietras, Gynec. Oncol.. 7:1 (1979)) or in their plasma membranes (Sylven, Virchows Arch. B.. 17:97 (1974); Sloane, Biomed. Biochim. Acta. 50:549 (1991 ); Keren, Cancer Res.. 48:1416 (1989); Pietras, J. Biol. Chem..
  • Tumors are proteolvtic (Fischer. Arch. Entw. Mech. Arg.. 104:210 (1925); Duffy, Eur. J. Cancer Clin. Oncol.. 23:583 (1987); Strauli et al., ed., "Proteinases and Tumor Invasion” (Raven Press, New York, 1980)), and this power is correlated with metastatic propensity (Duffy, Eur. J. Cancer Clin. Oncol.. 23:583 (1987); Sylven, Virchows Arch. B.. 17:97 (1974); Sloane,
  • Enzymes known to be secreted by metastasizing cells include cathepsin B (Sloane, Biomed. Biochim. Acta. 50:549 (1991 ); Keren, Cancer Res.. 48:1416 (1989); Pietras, J. Biol. Chem.. 256:8536 (1981 ); Weiss, Proc. Am. Assoc. Cancer Res...
  • cytotoxic drugs at the sites of metastatic foci.
  • Preferred drugs are those that are readily ingested by cells such as doxorubicin (Dox) (also known as adriamycin (ADM)), mitomycin C (MMC), taxol, camptothecin (CPT), and esperamycin, as well as derivatives of these drugs.
  • Dox doxorubicin
  • MMC mitomycin C
  • CPT camptothecin
  • esperamycin esperamycin
  • anticancer drugs have substantial hydrophobic moieties so that they can pass through the plasma membrane of metastatic cells.
  • Other anticancer drugs can be derivatized with appropriate hydrophobic moieties to improve their permeability to the lipid bilayer of the plasma membrane of the metastatic cell.
  • a particularly useful enzyme with prodrugs according to the present invention is cathepsin B, principally because it is an exopeptidase (Takahashi, J. Biol. Chem.. 261 :9375 (1986); Koga, J. Biochem.. 110:179 (1991)) for which numerous peptide substrates are already known (Dingle, ed., “Lysosomes” (North-Holland, Amsterdam, 1977); Strauli et al., eds., “Proteinases and Tumor Invasion” (Raven Press, New York, 1980); Neuberger, ed., "Hydrolytic Enzymes” (Elsevier, Amsterdam, 1987)).
  • Cathepsin B is a lysosomal enzyme that is ubiquitous within cells (Dingle, ed., “Lysosomes” (North-Holland, Amsterdam, 1977); Strauli et al., eds., “Proteinases and Tumor Invasion” (Raven Press, New York, 1980); Neuberger, ed., “Hydrolytic Enzymes” (Elsevier, Amsterdam, 1987)), but almost never secreted normally. If small amounts of cathepsin B do escape during exocytosis or unprogrammed cell death, it loses all activity within 15 minutes at neutral pH (Sheahan, Cancer Res..
  • the plasma membrane is obviously a highly desirable place to activate a latent cytotoxic drug which should be delivered, not only as directly as possible to the target cells, but also to neighboring cancer cells that might not display as much cathepsin B as the majority, owing to the high genetic instability (Fidler, Cancer Treat. Rep.. 68:193 (1984)) of metastasizing cells.
  • a preferred reagent for delivering therapeutic drugs to metastasizing cells is a hydrolyzable prodrug comprising an amino-terminal capped peptide covalently linked to a therapeutic drug through a self-immolating spacer of sufficient length to prevent the occurrence of steric hindrance.
  • the amino-terminal capped peptide is a substrate for a peptidohydrolase located on the surface of a metastatic cell.
  • the peptidohydrolase is cathepsin B or collagenase
  • the peptidohydrolase is cathepsin B.
  • the amino-terminal capped peptide that acts as a substrate for the peptidohydrolase is typically one of benzyloxycarbonylphenylalanyllysine, benzyloxycarbonylvalinyllysine, D-phenylalanylphenylalanyllysine, benzyloxycarbonylvalinylcitrulline, t-butyloxycarbonylphenylalanylysine, benzyloxycarbonylalanyllarginylarginine, benzyloxycarbonylphenylalanyl-N- tosylarginine,2-aminoethylthio-succinimidopropionylvalinylcitrulline, 2- aminoethylthio-succinimidopropionyllysylphenylalanyllysine,
  • the amino-terminal capped peptide is benzyloxycarbonylphenylalanyllysine or acetylphenylalanyllysine.
  • substrates containing paired basic residues can be hydroiyzed by cathepsin B (J.K. McDonald & S. Ellis, Life Sci.. 17:1269-1276 (1975)).
  • the amino-terminal residue must be "capped” or protected with a protecting group.
  • protecting groups are well-known in peptide chemistry and include, for example, benzyloxycarbonyl (also known as carbobenzoxy and generally abbreviated as Z), acetyl, 2-aminoethylthio-succinimidopropionyl, t-butyloxycarbonyl, and other amino-terminal protecting groups such as those disclosed in M. Bodanszky, "Principles of Peptide Synthesis” (2d Ed., Springer-Verlag, Berlin, 1993).
  • These groups include triphenylmethyl, ⁇ - methoxybenzyloxycarbonyl, adamantyloxycarbonyl, biphenylylisopropyloxycarbonyl, formyl. isonicotinyloxycarbonyl, o- nitrophenylsulfenyl, 9-fluorenylmethyloxycarbonyl, derivatives of benzyloxycarbonyl substituted on the aromatic ring of the benzyl group, or, in some cases, in which the phenyl moiety of the benzyl group is replaced with another fully aromatic moiety such as furan or pyndine, phthaloyl, dithiasuccinyl, p-toluenesulfonyl (tosyl), and other groups.
  • the amino-terminal protecting group can be a D- amino acid such as D-phenylalanine.
  • the amino-terminal protecting group is a D-amino acid
  • the carboxyl group of the D-amino acid forms a peptide bond with the amino-terminal residue of the amino-terminal protected peptide.
  • the protecting group is benzyloxycarbonyl or acetyl, so that the amino-terminal protected peptide is benzyloxycarbonylphenylalanyllysine or acetylphenylalanyllysine.
  • the hydrolyzable prodrug includes a spacer of sufficient length to prevent the occurrence of ste c hindrance between the amino-terminal protected peptide and the therapeutic drug. If the spacer is too short, the therapeutic drug may prevent the binding of the substrate for the peptidohydrolase to the active site of the peptidohydrolase by stenc hindrance.
  • a particularly suitable spacer is ⁇ _-am ⁇ nobenzyl carbonyl ("PABC"). This has an approximate length of 10 angstroms.
  • Derivatives of p-aminobenzyl carbonyl can also be used, such as compounds substituted on the aromatic moiety of the benzyl group.
  • spacer groups can be used.
  • the length of the spacer should be greater than about 10 angstroms; spacers of significantly greater length can be used, and can incorporate, for example, additional aliphatic or aromatic moieties. In general, such spacers should be relatively unbranched so as not to introduce stenc hindrance of their own.
  • the chemical functionality terminating the spacer can vary but one end is able to react with the carboxyl-terminal residue of the substrate for the peptidohydrolase. Typically, this is an amino group.
  • the other functionality terminating the spacer is capable of reacting with the therapeutic drug. In one preferred embodiment, this functionality reacts at an amino group of the drug to form a carbamate or urethane linkage as part of the spacer.
  • This spacer also reacts at an amino group of the drug to form a carbamate or urethane linkage.
  • This spacer is bifunctional and can bind two drug moieties such as doxorubicin.
  • such spacers have the property of self-immolation.
  • a self-immolating spacer is one in which the residual portion of the spacer attached to the therapeutic drug subsequent to the hydrolysis of the peptide bond by the peptidohydrolase is then further cleaved by spontaneous, nonenzymatic hydrolysis in an aqueous medium to restore the original unconjugated drug.
  • Both PABC and BHMS are self-immolating.
  • the spacer is p_-aminobenzyl carbonyl ("PABC") and the therapeutic drug is doxorubicin
  • PABC p_-aminobenzyl carbonyl
  • doxorubicin the portion of the spacer remaining attached to the drug after hydrolysis of the peptide bond by cathepsin B, then subsequently undergoes spontaneous hydrolysis to ⁇ _-aminobenzyl alcohol, carbon dioxide, and doxorubicin.
  • the therapeutic drug is an anticancer drug.
  • other therapeutic drugs can be incorporated into hydrolyzable prodrugs according to the present invention and can be delivered to metastatic cells.
  • Preferred anticancer drugs incorporated into hydrolyzable prodrugs according to the present invention include doxorubicin, taxol, camptothecin, mitomycin C, and esperamycin, as well as derivatives thereof.
  • Other anticancer drugs that have hydrophobic moieties that allow them to be taken up efficiently by metastatic cells or that can be derivatized with such moieties can also be used.
  • hydrolyzable prodrugs include benzyloxycarbonylphenylalanyllysyl- ⁇ -aminobenzyl carbamoyldoxorubicin, acetylphenylalanyliysyl-p_-aminobenzyl carbamoyldoxorubicin, acetylphenylalanyllysyl-p_-aminobenzyl carbamoylmitomycin C, benzyloxycarbonylphenylalanyllysyl- _-aminobenzyl carbonyl-7-paclitaxel, acetylphenylalanyllysyl-p_-aminobenzyl carbonylcamptothecin, 2- aminoethylthio-succinimidopropionyl-valinylcitrullinyl-bis(hydroxymethyl)- styryl-bisdoxorubicin, 2-aminoethylthi
  • Synthesis of hydrolyzable prodrugs according to the present invention can be accomplished by condensation reactions that are well known in the art. Examples of syntheses are given below in Examples 1 -6.
  • the synthetic procedure comprises: (1 ) synthesizing the peptide that is the substrate of the peptidohydrolase by conventional peptide synthetic techniques, with the ⁇ -amino group of the amino-terminal amino acid residue protected and appropriate protection for reactive side chains of the amino acids; (2) linking the g-aminobenzyl moiety to the carboxyl group of the carboxyl-terminal amino acid; (3) activating the j-aminobenzyl moiety for covalent linkage of the therapeutic drug; (4) covalently linking the therapeutic drug, which may have certain reactive side chains protected as well; and (5) removing the remaining protecting groups on the peptide and the therapeutic drug.
  • the synthetic procedure comprises: (1) synthesizing a peptide that is the substrate of the peptidohydrolase by conventional peptide synthetic techniques, with appropriate protective groups as above; (2) linking the BHMS moiety to the carboxyl group of the carboxyl-terminal amino acid of the peptide; (3) activating the BHMS moiety for coupling of the therapeutic drug; (4) coupling the therapeutic drug to the activated BHMS moiety; (5) removing any protecting groups on amino acid side chains, such as the ⁇ -amino group of lysine; and (6) modifying the amino-terminal blocking group so that the desired capping group is present.
  • the substrate for cleavage by the peptidohydrolase is a tripeptide or peptide with more than three amino acids
  • the peptide can be extended at its amino-terminus after the coupling of the carboxyl-terminus to the spacer. This involves removing the amino-terminal protecting group of the peptide, activating the carboxyl group of the amino acid to be added, and coupling it to the deblocked amino group to form a peptide bond. This step can be repeated if a longer peptide is desired. Then, the therapeutic drug is coupled to the completed peptide and synthesis of the hydrolyzable prodrug is completed as above.
  • the hydrolyzable prodrug further comprises a peptide derived from a protein that adheres to metastatic cells.
  • peptides include peptides derived from the protein fibronectin (GRGDS)(SEQ ID NO:1)(Humphries, Science 233:467 (1986); Olden. Ann. New York Acad. Sci. 421 (1989); Dedhar, Bjo Essays. 12:583 (1990)) and laminin (YIGSR)(SEQ ID NO:2)(lwamoto, Science. 238:1132 (1987); Saiki, Brit. J. Cancer 59:194 (1989)).
  • GAGDS protein fibronectin
  • YIGSR laminin
  • the peptide is covalently linked to the amino side of the amino-terminal capped peptide that is the substrate for the peptidohydrolase, either directly as an amide, or indirectly via attachment to the capping group, benzyloxycarbonyl, acetyl, maleimidopropionyl or the like, which has been modified to accept the peptide.
  • the linkage can be through either the amino or carboxyl group of the peptide, or, in some cases, through functional groups of the peptide such as the carboxyl of aspartic acid, the hydroxyl of serine or other functional groups of other residues.
  • various cross-linking reagents can be used.
  • carbodiimides such as dicyclohexylcarbodiimide
  • Other reactive groups are known and are described, for example, in G.T. Hermanson, "Bioconjugate Techniques” (Academic Press, San Diego, 1996), in S.S. Wong, “Chemistry of Protein Conjugation and Crosslinking” (CRC Press, Boca Raton, Fla. 1991), and in T.E. Creighton, Ed., "Protein Function: A Practical Approach” (IRL Press, Oxford 1989).
  • the peptide can be linked, for example, to a maleimidopropionyl cap via a cysteine whose thiol group is added to the maleimido group, or to a glycine or other amino acid cap (replacing the acetyl cap) via acylation of the amino group of the glycine, or by attaching the peptide to the reposition of the benzyloxycarbonyl cap, or by other methods known to the art.
  • the linkage of these peptides such as YIGSR (SEQ ID NO: 2) to the prodrug may be with or without intervening links which might or might not consist of other amino acids.
  • conjugation or crosslinking methods can also be used to attach the peptides such as the peptides from laminin or fibronectin to other portions of the hydrolyzable prodrug,. tn most cases, attaching the peptide to the self-immolating spacer would either prevent hydrolysis of the substrate by the peptidohydrolase or result in steric hindrance.
  • a number of peptides derived from the fibronectin and laminin peptides can be linked to the hydrolyzable prodrugs. These peptides can be classified in terms of their structure and homology to the fibronectin or laminin sequence as follows:
  • Fibronectin-derived peptides include: (1) the GRDGS (SEQ ID NO: 1) pentapeptide derived from the fibronectin sequence (I. Hardan et al., "Inhibition of Metastatic Cell Colonization in Murine Lungs and Tumor- Induced Morbidity by Non-Peptidic Arg-Gly-Asp Mimetics," Int. J. Cancer 55: 1023-1028 (1993)); (2) derivatives of the fibronectin pentapeptide sequence with conservative amino acid substitutions, such as GRGES (SEQ ID NO: 3) (R.J.
  • GRGDSPA SEQ ID NO: 8
  • GRGDXPC extended peptides with ammo acid substitutions, such as GRGDXPC, where X is a naturally-occurring L-amino acid other than M, C, H, Y, G, or P
  • GRGDNPC SEQ ID NO: 9
  • GRGDXPA GRGDXPA
  • X is a naturally-occurring L-amino acid other than M, C, H, Y, G, or P
  • GRGDSG SEQ ID NO: 1 1
  • YIGSR Multimeric Forms of Tyr-lle-Gly-Ser-Arg
  • GRGDXG where X is a naturally-occurring L-amino acid other than M, C, H, Y, G, or P
  • GRDGXPA where X is a naturally-occurring L-amino acid other than M, C, H, Y, G, or P
  • Laminin-derived peptides include: (1 ) the YIGSR (SEQ ID NO:
  • CDPGYIGSR SEQ ID NO: 17
  • peptides including substituted peptides and extended sequences with amino acid substitutions, in which a D-amino acid replaces one of the naturally occurring L-amino acids, such as CDPGYI(dA)SR and YIG(dA)SR (G.J. Ostheimer et al., "NMR Constrained Solution Structures for Laminin Peptide 11.” J. Biol. Chem.
  • An additional aspect of the present invention is a method for delivery of a therapeutic drug to a metastatic cell.
  • a method for delivery of a therapeutic drug to a metastatic cell comprises the steps of:
  • a hydrolyzable prodrug comprising an amino- terminal capped peptide covalently linked to a therapeutic drug through a self-immolating spacer of sufficient length to prevent the occurrence of steric hindrance with a metastatic cell, the amino-terminal capped peptide being a substrate for a peptidohydrolase located on the surface of the metastatic cell;
  • the therapeutic drug is an anticancer drug.
  • the hydrolyzable prodrug is delivered to the metastatic cells under conditions under which the prodrug is stable in the absence of enzymatic hydrolysis.
  • prodrugs are stable in plasma at pH 7.4 at 37 9 C. for at least 6 days in the absence of a peptidohydrolase such as cathepsin B.
  • the prodrugs are stable for 16 days or more or 20 days or more in the absence of cathepsin B.
  • the prodrug can be delivered to the metastatic cells either in vivo or in vitro.
  • the hydrolyzable prodrugs of the present invention are administered in a quantity sufficient to kill at least a fraction of the metastatic cells.
  • the hydrolyzable prodrugs of the present invention can be administered in vivo using conventional modes of administration including, but not limited to, intravenous, intraperitoneal, oral or intralymphatic. Other routes of injection can alternatively be used. Oral or intraperitoneal administration is generally preferred.
  • the composition can be administered in a variety of dosage forms which include, but are not limited to, liquid solutions or suspensions, tablets, pills, powders, suppositories, polymeric microcapsules or microvesicles, liposomes, and injectable or infusible solutions. The preferred dosage form depends on the mode of administration and the quantity administered.
  • compositions for administration according to the present can include conventional pharmaceutically acceptable carriers and adjuvants known in the art such as human serum albumin, ion exchangers, alumina, lecithin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate.
  • conventional pharmaceutically acceptable carriers and adjuvants known in the art such as human serum albumin, ion exchangers, alumina, lecithin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate.
  • the most effective modes of administration and dosage regimen for the hydrolyzable prodrugs as used in the methods of the present invention depend on the severity and course of the disease, the patient's health, the response to treatment, the particular type of metastatic cells characteristic of the particular primary tumor, the location of the metastases, pharmacokinetic considerations such as the condition of the patient's liver and/or kidneys that can affect the metabolism and/or excretion of the administered hydrolyzable prodrugs, and the judgment of the treating physician. Accordingly, the dosages should be titrated to the individual patient.
  • the invention is further exemplified by the following Examples. These examples are for illustrative purposes only and are not intended to limit the scope of the invention.
  • hydrolyzable prodrug is acetylphenyialanyllysyl-p-aminobenzyl carbonylcamptothecin (Ac-Phe-Lys-PABC-CPT).
  • Fmoc-Phe-Lys-(Boc)- PABC-CPT 200 mg, 0.18 mmol was suspended in 6.0 mi of methylene chloride and 1.0 ml of diethylamine added. The suspension gradually dissolved as the solution and was stirred for 3 h. The solvent and diethylamine were removed under vacuum. The resulting foamy solid was redissolved in methylene chloride and then acetic anhydride (0.068 ml, 0.72 mmol) and diisopropylethylamine (0.13 mol) added. The reaction mixture was stirred overnight, transferred to a separatory funnel, and washed with pH 7 buffer.
  • This bifunctional spacer can bind two doxorubicin molecules.
  • This compound also has a capping group of 2-aminoethylthio (CA) linked to the valine residue through a succinimidopropionyl (SP) group.
  • CA 2-aminoethylthio
  • SP succinimidopropionyl
  • Fmoc-Lys The first step in the synthesis of the hydrolyzable prodrug Ac-Phe-Lys-PABC-Dox is the synthesis of Fmoc- Lys (MMT).
  • This lysine derivative has its ⁇ -amino group protected with the protecting group 9-fluorenylmethoxycarbonyl and its ⁇ -amino group protected with the blocking group monomethoxytrityl.
  • hydrolyzable prodrug according to the present invention with an acetyl capping group and mitomycin C (MMC) as the anticancer drug was synthesized.
  • the peptide substrate for cathepsin B is Phe-Lys. Synthesis of Ac-Phe-Lvs(MMT)-PABC-MMC.
  • the first step in the synthesis is the coupling of the phenylalanyl moiety with the lysine moiety, whose ⁇ - amino group is protected with a monomethoxytrityl (MMT) residue. Coupling is accomplished with the use of a succinimidyi derivative of the phenylalanine, whose carboxyl group is thereby activated.
  • the first step in the synthesis of the bifunctional hydrolyzable prodrug CA-SP- Lys-Phe-Lys-BHMS-Dox 2 is a synthesis of the bifunctional linker bis(hydroxymethyl)p_-aminostyrene (BHMS).
  • Raney nickel (5.28 ml, 50% slurry in H 2 0) and hydrazine monohydrate (21 ml, 1.5 equiv.) were added to a stirred solution of 2-(p-nitrobenzylidene)-propane-1 ,3-diol (P. Vanelle et al., Eur. J. Med. Chem.
  • the BT-20 cell line was maintained in E-MEM-10 (minimal essential medium (Earle's Salts) supplemented with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 ⁇ g/ml)) in 5% C0 2 at 37° C.
  • E-MEM-10 minimal essential medium (Earle's Salts) supplemented with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 ⁇ g/ml)
  • MCF 10A cell line was maintained in DMEM/Ham's F12 supplemented with 5% horse serum, EGF (20 ng/ml), insulin (0 5 ⁇ g/ml), hydrocortisone (0.5 ⁇ g/ml), penicillin (100 U/ml), and streptomycin (100 ⁇ g/ml) in 5% C0 2 at 37 9 C Corning tissue culture multiwell plates (24 wells/plate) were seeded with 10 5 cells/16 mm well in 2 ml maintenance medium, refed 48 h after seeding and were ready to use in cytotoxicity assays 4 8h later, with the cells just reaching confiuency.
  • cytotoxicity assay protocol employing MCF 10A (low cathepsin B secreters) and BT-20 (high cathepsin B secreters) and inhibition of cytotoxicity with L- trans-epoxysuccmyl-leucylamido (4-guan ⁇ do) butane (cysteine protease inhibitor) or CA-074 (N-(L-3-trans-propylcarbamoylox ⁇ rane-2-carbonyl)-L- ⁇ soleucyl-L-prol ⁇ ne)(spec ⁇ f ⁇ c cathepsin B inhibitor) was standardized with the only variations occurring with compound, molar concentration, time of exposure, and presence or absence of inhibitors Maintenance medium was aspirated from the cell walls after feeding, and the cells washed twice with 2 ml/well Hanks balanced salt solution (HBSS).
  • HBSS Hanks balanced salt solution
  • Compound (1) was Ac-Phe-Lys-PABC-Dox
  • Compound (2) was Ac-Phe-Lys-PABC-MMC
  • Compound (3) was Ac-Phe- Lys-PABC-CPT
  • Compound (4) was Z-Phe-Lys-PABC-7-Paclitaxel
  • Compound (5) was CA-SP-Val-Cit-BHMS-Dox 2
  • Compound (6) was CA- SP-Lys-Phe-Lys-BHMS-Dox 2
  • Compound (7) was Z-Phe-Lys-Dox
  • Compound (8) was 2-Hydroxyethytthio-SP-D-Phe-Lys-PABC-Dox.
  • MMC is mitomycin C
  • CPT is camptothecin
  • Z is benzyloxycarbonyl
  • CA is 2-aminoethylthio
  • SP is succinimidopropionyl
  • PABC is p_-aminobenzyl carbonyl
  • CA-074 The killing of high cathepsin B-secreting cells was inhibited by CA-074.
  • CA-074 does not inhibit this killing because it does not enter lysosomes.
  • Compounds (7) and (8) are control compounds, weaker cytotoxic agents than Compounds (1) and (2) because they are less susceptible to cathepsin B- mediated hydrolysis to an active drug because of their particular structures.
  • Compound (7) lacks the PABC-self-immolating linker that facilitates enzymatic cleavage, resulting in probable steric hindrance that places the bulky doxorubicin moiety in the active site of the cathepsin B.
  • Compound (8) has the amino acids in the unnatural D instead of the natural L configuration.
  • Figure 10 depicts the percent cell kill at various times and prodrug concentrations with BT-20 cells.
  • the results with CA-074 present at 40 ⁇ M are given in parentheses. The results indicate that all test compounds show dose- and time-dependent killing of BT-20 (cathepsin B+) ceils.
  • the cathepsin B inhibitor CA-074 strongly inhibits cytotoxicity.
  • Compound (8), the compound containing the amino acids in the D- configuration, is very much less active.
  • tumor cells do indeed secrete enough cathepsin B to release enough cytotoxic drug to kill the cells efficiently. Tumor cells that secrete less cathepsin B are resistant to the hydrolyzable prodrugs.
  • Cathepsin B inhibitors strongly reduce cytotoxicity of the prodrugs, showing that cathepsin B is the principal means of unmasking them.
  • a prodrug lacking the self-immolating linkers PABC or BHMS has much reduced cytotoxicity, showing that it is an enzyme, presumably cathepsin B, that releases active drug. This is because the absence of the self-immolating linker results in steric hindrance.
  • a prodrug with amino acids in the unnatural D configuration has much reduced cytotoxicity, again showing the role of cathepsin B.
  • Figure 12 shows the stability of a number of hydrolyzable prodrugs according to the present invention linked to doxorubicin using a PABC-self-immolating linker.
  • These hydrolyzable prodrugs release anticancer drug under cathepsin B catalysis at 37°C, pH 7.4, at reasonable rates, and are stable for days or weeks in freshly drawn human plasma under the same conditions.
  • the present invention provides an efficient way to treat cancer cells secreting peptidohydrolases on their surface, particularly metastatic cells.
  • the hydrolyzable prodrugs of the present invention are usable against many types of metastases and do not depend for their activity on characteristics of the primary tumor cells that might not be shared by the metastases. Hydrolyzable prodrugs of the present invention are readily absorbed and lack toxicity.

Abstract

Les promédicaments hydrolysables selon l'invention sont activés par des protéases situées dans les membranes cellulaires de cellules métastatiques, de sorte que soient produits des médicaments anticancéreux actifs pouvant être absorbés par les cellules métastatiques. En général, un promédicament hydrolysable selon l'invention, comprend un peptide coiffé d'un N-terminal et qui constitue un substrat pour une peptidohydrolase située à la surface d'une cellule métastatique liée de manière covalente à un médicament thérapeutique par l'intermédiaire d'un espaceur à auto-immolation présentant une longueur suffisante pour empêcher l'apparition d'un empêchement stérique. Le médicament thérapeutique est généralement un médicament anti-cancéreux, généralement de la doxorubicine, du taxol, de la camptothécine, de la mitomycine C ou de l'espéramycine. Généralement, la peptidohydrolase qui hydrolyse le substrat du promédicament hydrolysable est de la cathepsine B.
EP97944519A 1996-09-27 1997-09-25 Promedicaments hydrolysables pour la liberation de medicaments anticancereux dans des cellules metastatiques Withdrawn EP0961619A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4433496P 1996-09-27 1996-09-27
US44334P 1996-09-27
PCT/US1997/017410 WO1998013059A1 (fr) 1996-09-27 1997-09-25 Promedicaments hydrolysables pour la liberation de medicaments anticancereux dans des cellules metastatiques

Publications (2)

Publication Number Publication Date
EP0961619A1 true EP0961619A1 (fr) 1999-12-08
EP0961619A4 EP0961619A4 (fr) 2001-09-26

Family

ID=21931799

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97944519A Withdrawn EP0961619A4 (fr) 1996-09-27 1997-09-25 Promedicaments hydrolysables pour la liberation de medicaments anticancereux dans des cellules metastatiques

Country Status (4)

Country Link
EP (1) EP0961619A4 (fr)
AU (1) AU739028B2 (fr)
CA (1) CA2264227A1 (fr)
WO (1) WO1998013059A1 (fr)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US6545125B1 (en) * 1997-11-18 2003-04-08 Chugai Seiyaku Kabushiki Kaisha Compounds with antitumor activity
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
WO1999030727A1 (fr) 1997-12-17 1999-06-24 Enzon, Inc. Prodrogues polymeriques d'agents bioactifs contenant amine ou hydroxy
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
AU3733399A (en) 1998-05-22 1999-12-13 Daiichi Pharmaceutical Co., Ltd. Drug composites
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6214330B1 (en) 1998-07-13 2001-04-10 Enzon, Inc. Coumarin and related aromatic-based polymeric prodrugs
JP2002530059A (ja) 1998-11-13 2002-09-17 サイクラセル・リミテッド 輸送ベクター
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6191290B1 (en) * 1999-02-24 2001-02-20 Uab Research Foundation Taxane derivatives for targeted therapy of cancer
JP2002544242A (ja) * 1999-05-14 2002-12-24 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 酵素活性化抗腫瘍プロドラッグ化合物
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
AU781380B2 (en) * 1999-09-07 2005-05-19 Conjuchem Biotechnologies Inc. Pulmonary delivery for bioconjugation
WO2002008174A1 (fr) * 2000-07-26 2002-01-31 Patrick Anthony Riley Derives de phenylethylamine et leur utilisation dans le traitement de melanome
US6919307B2 (en) 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
PL366216A1 (en) 2000-11-01 2005-01-24 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7105482B2 (en) 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
EP1243276A1 (fr) * 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Prodrogues activables à séparateurs allongés et multiples
JP4109123B2 (ja) * 2001-05-09 2008-07-02 セルメド オンコロジー （ユーエスエイ）， インコーポレイテッド ペプチドデホルミラーゼ活性化プロドラッグ
CN1615131A (zh) * 2001-11-23 2005-05-11 中外制药株式会社 肿瘤靶向酶的鉴定方法
AU2002358086B2 (en) 2001-12-03 2009-06-04 Universitatsklinikum Charite Der Humboldt-Universitat Zu Berlin Technologie Transferstelle Podophyllotoxins as antiproliferative agents
JP2006503545A (ja) * 2002-02-14 2006-02-02 ラター， ウィリアム ジェイ． 処置される宿主における切断についてのキメラ分子
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
AU2003243380A1 (en) 2002-06-03 2003-12-19 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
EP2357006B1 (fr) 2002-07-31 2015-09-16 Seattle Genetics, Inc. Conjugués de médicaments et leur utilisation pour traiter le cancer, maladie auto-immune ou maladie infectieuse
AU2003256038A1 (en) * 2002-08-30 2004-03-19 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
WO2004043400A2 (fr) 2002-11-14 2004-05-27 Celmed Oncology (Usa), Inc. Promedicaments actives par peptide deformylase
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
WO2004111192A2 (fr) 2003-05-29 2004-12-23 The Scripps Research Institute Liberation ciblee sur des cellules exprimant la legumaine
US7232805B2 (en) * 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
BR122018071968B8 (pt) 2003-11-06 2021-07-27 Seattle Genetics Inc conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
EP1718667B1 (fr) * 2004-02-23 2013-01-09 Genentech, Inc. Liants et conjugues heterocycliques auto-immolateurs
CA2563502A1 (fr) 2004-04-09 2005-10-20 Chugai Seiyaku Kabushiki Kaisha Nouveau promedicament soluble dans l'eau
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060188508A1 (en) 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
EP2722051B1 (fr) 2005-07-07 2018-11-07 Seattle Genetics, Inc. Composés de monométhylvaline présentant des modifications de la chaîne latérale de phénylalanine au niveau de la terminaison C
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
JP5523313B2 (ja) 2007-07-03 2014-06-18 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド ポリシアル酸誘導体、製造方法、ならびにがん抗原産生の増強およびターゲティングにおける使用
KR20230003298A (ko) 2008-04-30 2023-01-05 이뮤노젠 아이엔씨 가교제 및 그 용도
WO2009143454A2 (fr) 2008-05-22 2009-11-26 Kereos, Inc. Combinaison thérapeutique anticancéreuse
WO2010005850A1 (fr) 2008-07-08 2010-01-14 The J. David Gladstone Institutes Procédés et compositions de modulation de l’angiogenèse
PE20130342A1 (es) 2010-04-15 2013-04-20 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas
CN102504013B (zh) * 2011-09-28 2014-03-26 李雁 一种靶向抗癌转移化学药物padm及制备方法和用途
PL2773671T3 (pl) 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
US20140364359A1 (en) * 2012-01-18 2014-12-11 Raymond A FIRESTONE Compositions and methods for treating cancer and inflammation-related dieseases and conditions
US20150335761A1 (en) * 2012-02-16 2015-11-26 Raymond Firestone Compositions and methods for contraception
WO2013173756A1 (fr) 2012-05-18 2013-11-21 University Of North Dakota Méthode de quantification de protéines et d'isoformes de ces protéines
WO2013177481A1 (fr) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazépines et leurs conjugués
JP6578206B2 (ja) 2012-07-19 2019-09-18 レッドウッド バイオサイエンス， インコーポレイテッド Ｃｄ２２に特異的な抗体およびその使用方法
PT2906296T (pt) 2012-10-12 2018-06-01 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpo
CA2887895C (fr) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Conjugues d'anticorps cd19-anti-pyrrolobenzodiazepine
KR101995621B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항-cd22 항체 컨주게이트
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
JP6270859B2 (ja) 2012-10-12 2018-01-31 エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａｒｌ ピロロベンゾジアゼピン−抗体結合体
WO2014057120A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps - pyrrolobenzodiazépine
RS53818B1 (en) 2012-10-12 2015-06-30 Spirogen Sàrl PIROLOBENZODIAZEPINI I NJIHOVI conjugated
EP2912177A1 (fr) 2012-10-23 2015-09-02 Cornell University Traitement du cancer du sein métastatique
WO2014074218A1 (fr) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Composés et procédés pour produire un conjugué
CN110452242A (zh) 2012-12-21 2019-11-15 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
SI3613439T1 (sl) 2013-02-15 2021-11-30 The Regents Of The University Of California Himerni antigenski receptor in postopki njegove uporabe
CA2905181C (fr) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines et ses conjugues servant a fournir une therapie ciblee
KR102057755B1 (ko) 2013-03-13 2019-12-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
WO2015038426A1 (fr) * 2013-09-13 2015-03-19 Asana Biosciences, Llc Lieurs auto-immolables contenant des dérivés d'acide mandélique, conjugués médicament-ligand pour thérapies ciblées, et leurs utilisations
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
US9493413B2 (en) 2013-11-27 2016-11-15 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
EP3107899B1 (fr) 2014-02-19 2020-08-12 Aviv Therapeutics, Inc. Amides polycycliques se liant à l'aldéhyde déshydrogénase 2 mitochondriale (aldh2) et leur utilisation pour le traitement du cancer
WO2015153401A1 (fr) 2014-04-04 2015-10-08 Merck Sharp & Dohme Corp Lieurs à base de phosphates pour introduction intracellulaire de conjugués médicamenteux
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
WO2016037644A1 (fr) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3223854A1 (fr) 2014-11-25 2017-10-04 ADC Therapeutics SA Conjugués anticorps-pyrrolobenzodiazépine
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
US10800826B2 (en) 2015-10-05 2020-10-13 Merck Sharp & Dohme Corp. Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
US11510993B2 (en) 2015-10-06 2022-11-29 Merck Sharp & Dohme Llc Antibody drug conjugate for anti-inflammatory applications
WO2017083637A1 (fr) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Oligophosphotriesters riches en guanidinium à pénétration cellulaire pour l'administration de médicament et de sonde
US20210206826A1 (en) 2015-11-19 2021-07-08 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
WO2017132103A2 (fr) 2016-01-29 2017-08-03 Merck Sharp & Dohme Corp. Lieurs de phosphonate et leur utilisation pour faciliter la rétention cellulaire de composés
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3231421A1 (fr) 2016-04-11 2017-10-18 Greenaltech, S.L. Utilisations d'un caroténoïde dans le traitement ou la prévention d'états induits par le stress
AU2017257504A1 (en) 2016-04-26 2018-10-25 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3463308B1 (fr) 2016-06-01 2021-12-01 Servier IP UK Limited Formulations d'oxyde de polyalkylène-asparaginase et leurs procédés de fabrication et d'utilisation
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
MX2019008503A (es) 2017-01-18 2019-09-13 F1 Oncology Inc Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP3388082A1 (fr) 2017-04-13 2018-10-17 Galera Labs, LLC Poly-immunothérapie anticancéreuse avec un complexe de cycle pentaaza macrocyclique
CN110582505B (zh) 2017-04-18 2021-04-02 免疫医疗有限公司 吡咯并苯并二氮杂*缀合物
CN110536703A (zh) 2017-04-20 2019-12-03 Adc治疗有限公司 使用抗axl抗体-药物缀合物的组合疗法
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
SI3668874T1 (sl) 2017-08-18 2022-04-29 Medimmune Limited Pirolobenzodiazepinski konjugati
EP3505188A1 (fr) 2017-12-29 2019-07-03 Invivogen Conjugués de dinucléotide pro-cycliques pour l'induction de la cytokine
CN111902147A (zh) 2018-01-31 2020-11-06 加莱拉实验室有限责任公司 五氮杂大环状环配合物和基于铂的抗癌剂的组合癌症治疗
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
CA3096838A1 (fr) 2018-04-11 2019-10-17 Ohio State Innovation Foundation Procedes et compositions pour microparticules a liberation prolongee pour l'administration de medicament oculaire
CN108383757A (zh) * 2018-04-12 2018-08-10 江苏金斯瑞生物科技有限公司 一种Nε-叔丁氧羰基-Nα-芴甲氧羰基-Nε-甲基-赖氨酸的制备方法
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA3105879A1 (fr) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugues pour administrer un agent anticancereux a des cellules nerveuses, methodes d'utilisation et leurs procedes de fabrication
CA3131895A1 (fr) 2019-04-02 2020-10-08 Kenjockety Biotechnology, Inc. Anticorps multi-specifiques d'un antigene associe a un cancer et d'une pompe d'efflux, ainsi que compositions, reactifs, kits et methodes associes a ceux-ci
CA3137373A1 (fr) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Conjugues anticorps-medicaments d'amatoxine et leurs utilisations
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN115023443A (zh) 2020-01-29 2022-09-06 肯乔克蒂生物技术股份有限公司 抗mdr1抗体及其用途
US20230192902A1 (en) 2020-06-04 2023-06-22 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
JP2023528416A (ja) 2020-06-04 2023-07-04 ケンジョッケティ バイオテクノロジー，インク． 抗ａｂｃｇ２抗体及びそれらの使用
WO2022043256A1 (fr) 2020-08-23 2022-03-03 Cobiores Nv Combinaisons synergiques de médicaments anticancéreux liés à une fraction tétrapeptidique et d'agents immunothérapeutiques
WO2022051390A1 (fr) 2020-09-02 2022-03-10 Kenjockety Biotechnology, Inc. Anticorps anti-abcc1 et leurs utilisations
WO2022103603A1 (fr) 2020-11-13 2022-05-19 Kenjockety Biotechnology, Inc. Anticorps anti-mrp4 (codés par le gène abcc4) et leurs utilisations
CA3203072A1 (fr) 2020-12-22 2022-06-30 Andrea CASAZZA Composes comprenant une fraction tetrapeptidique
WO2022167664A1 (fr) 2021-02-07 2022-08-11 Cobiores Nv Composés comprenant une fraction tétrapeptidique
WO2023114658A1 (fr) 2021-12-13 2023-06-22 Kenjockety Biotechnology, Inc. Anticorps anti-abcb1
WO2023159220A1 (fr) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anticorps anti-cd47
US20230355792A1 (en) 2022-04-07 2023-11-09 Heidelberg Pharma Research Gmbh Methods of improving the therapeutic index

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019705A1 (fr) * 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Sequences de liaison peptidiques ramifiees

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019705A1 (fr) * 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Sequences de liaison peptidiques ramifiees

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUBOWCHIK, GENE M. ET AL: "Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin" BIOORG. MED. CHEM. LETT. (1998), 8(23), 3341-3346 , XP002172918 *
DUBOWCHIK, GENE M. ET AL: "Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (taxol), mitomycin C and doxorubicin" BIOORG. MED. CHEM. LETT. (1998), 8(23), 3347-3352 , XP002172917 *
DUBOWCHIK, GENE M. ET AL: "Monomethoxytrityl (MMT) as a versatile amino protecting group for complex prodrugs of anticancer compounds sensitive to strong acids, bases and nucleophiles" TETRAHEDRON LETT. (1997), 38(30), 5257-5260 , July 1997 (1997-07), XP002172916 *
See also references of WO9813059A1 *

Also Published As

Publication number Publication date
WO1998013059A1 (fr) 1998-04-02
AU4599597A (en) 1998-04-17
CA2264227A1 (fr) 1998-04-02
AU739028B2 (en) 2001-10-04
EP0961619A4 (fr) 2001-09-26

Similar Documents

Publication Publication Date Title
AU739028B2 (en) Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
US7816317B2 (en) Tripeptide prodrug compounds
JP3607201B2 (ja) Ｆａｐ活性化抗腫瘍性化合物
ES2282130T3 (es) Nuevos efectores de la dipeptidil peptidasa iv para la aplicacion topica.
AU2002316539C1 (en) CD10-activated prodrug compounds
US6855689B2 (en) Enzyme-activated anti-tumor prodrug compounds
KR100387191B1 (ko) 캄프토테신유도체
JP3173786B2 (ja) トロンビンの阻害剤および基質
RU2149646C1 (ru) Полимерный конъюгат, фармацевтическая композиция
WO2015106599A1 (fr) Conjugués et compositions pour une administration médicamenteuse
JP2006507322A (ja) 多重自己脱離放出スペーサーとして構築されたプロドラッグ
EP1753776B1 (fr) Camptothecines conjuguees en position 7 avec des peptides cycliques utilisees comme agents cytostatiques
KR20090057235A (ko) 리신계 폴리머 링커
WO1998013381A1 (fr) Proteines modifiees physiologiquement actives et compositions medicamenteuses les contenant
JP2005500997A (ja) トリメチルロック型テトラパルテートプロドラッグ
JP2011523415A (ja) 新規な二重標的化抗腫瘍複合体
US10413614B2 (en) Conjugates for protection from nephrotoxic active substances
US7064105B2 (en) Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them
WO2002007770A2 (fr) Conjugues polymeres d'agents antitumoraux
CA2176414A1 (fr) Promedicaments a base de guanidine et d'amidine acylees
EP0644181B1 (fr) Derive d'acides amines et son utilisation
US20070232639A1 (en) Camptothecin Derivatives Conjugated in Position 20 with Integrin Antagonists
CA3171025A1 (fr) Ligands de proteine d'activation des fibroblastes pour applications d'administration ciblee
KR20040008135A (ko) 메탈로 매트릭스프로테이나제에 의해서 활성화되는 종양표적 프로드러그
WO1997010262A1 (fr) Derives peptidiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990426

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010813

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030124

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040906